Norcantharidin is a synthetic anticancer compound. norcantharidin was compared with adriamycin and mitomycin C for its inhibitory action in the growth of cultured human hepatocellular carcinoma HepG2 cells. The IC50 of adriamycin and mitomycin C on HepG2 cells was 7.3 microM and 27 microM, respectively, whereas the IC50 of norcantharidin for inhibiting the growth of HepG2 cells was as high as 1900 microM. After HepG2 tumor-bearing nude mice were treated with 12 daily intraperitoneal injections of norcantharidin (2 mg/kg), the increase in tumor size was significantly slower than that of untreated controls. The mean survival time of untreated tumor-bearing nude mice was 129 days, whereas in the tumor-bearing nude mice treated with norcantharidin, the mean survival time was significantly prolonged to 194 days (P < 0.0001). It is concluded that norcantharidin may have a potential role in the treatment of human hepatocellular carcinoma.
Organism species: Pan-species (General)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Complete Antigen of Norcantharidin (NCTD) | Antigenic Transformation Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Norcantharidin (NCTD) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Norcantharidin (NCTD) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Norcantharidin (NCTD) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Norcantharidin (NCTD) | ELISA Kit Customized Service Offer |